Agios Pharmaceuticals, Inc. (LON:0HB0)
London · Delayed Price · Currency is GBP · Price in USD 36.47
+0.26 (0.71%)
At close: Sep 15, 2025
Agios Pharmaceuticals Employees
As of December 31, 2024, Agios Pharmaceuticals had 488 total employees, including 486 full-time and 2 part-time employees. The number of employees increased by 102 or 26.42% compared to the previous year.
Employees
488
Change (1Y)
102
Growth (1Y)
26.42%
Revenue / Employee
61.26K GBP
Profits / Employee
974.32K GBP
Market Cap
1.56B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 488 | 102 | 26.42% |
| Dec 31, 2023 | 386 | -7 | -1.78% |
| Dec 31, 2022 | 393 | 1 | 0.26% |
| Dec 31, 2021 | 392 | -170 | -30.25% |
| Dec 31, 2020 | 562 | 26 | 4.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| HUTCHMED (China) | 1,811 |
| Genus | 3,500 |
Agios Pharmaceuticals News
- 1 day ago - AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm - Business Wire
- 3 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO - PRNewsWire
- 6 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO - GlobeNewsWire
- 8 days ago - Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive - Seeking Alpha
- 12 days ago - HC Wainwright & Co. Reiterates Buy Rating on AGIO with $56 Target | AGIO Stock News - GuruFocus
- 12 days ago - Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated - Seeking Alpha
- 12 days ago - FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use - Benzinga
- 13 days ago - Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia - GlobeNewsWire